Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of catumaxomab as
consolidation treatment in patients with epithelial ovarian cancer in second or third
complete remission.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Investigación en Cáncer de Ovario